BioSpace1h
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
BioSpace1h
Good Day for Gardasil as Merck Wins Safety Suit, Drops $1B for Manufacturing Push
According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...
BioSpace2h
Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...
BioSpace7h
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs
Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, ...
BioSpace8h
16 Years And 3 Texas Two-Steps Later, J&J’s Talc Lawsuit Awaits Key Ruling
Johnson & Johnson has been fighting thousands of lawsuits over its now-discontinued talc products for 16 years. A pending ...
BioSpace4h
COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, ...